Structural aspects and physiological consequences of APP/APLP trans-dimerization by Baumkötter, Frederik et al.
REVIEW
Structural aspects and physiological consequences of APP/APLP
trans-dimerization
Frederik Baumko ¨tter • Katja Wagner •
Simone Eggert • Klemens Wild • Stefan Kins
Received: 1 July 2011/Accepted: 13 September 2011/Published online: 28 September 2011
 The Author(s) 2011. This article is published with open access at Springerlink.com
Abstract The amyloid precursor protein (APP) is one of
the key proteins in Alzheimer’s disease (AD), as it is the
precursor of amyloid b (Ab) peptides accumulating in
amyloid plaques. The processing of APP and the pathogenic
features of especially Ab oligomers have been analyzed in
detail. Remarkably, there is accumulating evidence from
cell biological and structural studies suggesting that APP
and its mammalian homologs, the amyloid precursor-like
proteins (APLP1 and APLP2), participate under physio-
logical conditions via trans-cellular dimerization in syna-
ptogenesis. This offers the possibility that loss of synapses
in AD might be partially explained by dysfunction of
APP/APLPs cell adhesion properties. In this review, struc-
tural characteristics of APP trans-cellular interaction will be
placed critically in context with its putative physiological
functions focusing on cell adhesion and synaptogenesis.
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Introduction
Alzheimer’s disease (AD) is a progressive neurodegene-
rative disorder, characterized by loss of neurons and
synapses in brain regions critical for cognition and memory
(reviewed in Selkoe 2002). Main pathological hallmarks
found in AD brains are neuroﬁbrillary tangles (NFT) and
amyloid plaques (Haass and Mandelkow 2010). Amyloid
plaques are extracellular protein deposits mainly composed
of a short insoluble peptide termed amyloid b (Ab), which
is generated by proteolytic processing from the amyloid
precursor protein (APP). APP is a type I transmembrane
protein with a large extracellular domain and a short
cytoplasmic tail. The extracellular domain is composed of
two subdomains termed E1 and E2 that are interconnected
by a highly acidic domain. The E1 domain is further sub-
divided into a growth factor-like domain (GFLD) and a
copper binding domain (CuBD) (reviewed in Reinhard
et al. 2005; Gralle and Ferreira 2007). Structural informa-
tion is available for the E1 and E2 domain as well as the
APP intracellular domain (AICD) and will be discussed
later on.
APP is one member of a gene family with two additional
homologs in mammals termed amyloid precursor-like
proteins (APLP1 and APLP2). These proteins display high
sequence homology and share a conserved domain struc-
ture, but the Ab sequence is unique to APP. Alternative
splicing of both APP and APLP2 gives rise to various
isoforms with different expression patterns, whereas only
one isoform of APLP1 has been detected so far (reviewed
in Jacobsen and Iverfeldt 2009). The Kunitz protease
inhibitor (KPI) domain is present in all splice variants of
APLP2 and in the two longer splice forms of APP (APP751
and APP770), which are expressed only at low levels in
neurons (Sandbrink et al. 1996). APP and APLP2 are
ubiquitously expressed, whereas APLP1 expression is
restricted to neurons (Slunt et al. 1994; Lorent et al. 1995;
Walsh et al. 2007). Analysis of mouse models with genetic
deletions of APP, APLP1 or APLP2 revealed a genetic
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single deletions were viable and fertile and showed only
mild phenotypes (reviewed in Anliker and Muller 2006;
Guo et al. 2011).
The proteolytic processing of APP by consecutive
cleavage of b- and c-secretases leading to the generation of
Ab peptides and release of the intracellular domain (AICD)
is well understood (reviewed in Jacobsen and Iverfeldt
2009). However, despite extensive studies, the physiolog-
ical functions of APP and its homologs remain still elusive.
Based on genetic studies, many different functions have
been proposed, including neuronal survival, cell migration,
axonal transport as well as central and peripheral syna-
ptogenesis, but so far the molecular mechanisms have
remained unclear (reviewed in Zheng and Koo 2011).
Some of these functions might be related to the extracel-
lular secreted forms of APP (sAPP) either released by a-o r
b-secretase, functioning as a ligand of a so far not clearly
identiﬁed receptor (Turner et al. 2003; Young-Pearse et al.
2008). However, other proposed functions of APP/APLPs,
such as cell migration and synaptogenesis, could be
explained by cell adhesion features of APP/APLPs, form-
ing trans-cellular homo- and heterotypic dimers or oligo-
meric complexes (Soba et al. 2005).
Dimerization of APP family members
There is accumulating evidence that APP and its mam-
malian homologs are able to form homo- and heterodimers
in cis and trans orientation at the cellular level. Protein
interaction in cis seems to have an impact on APP pro-
cessing and Ab generation (Kaden et al. 2008; Eggert et al.
2009), whereas interaction in trans promotes cell adhesion
and synaptogenesis (Soba et al. 2005; Wang et al. 2009b).
In this review, we are focusing on structural aspects and
physiological consequences of APP trans-dimerization.
It has been shown that APP homo- and heterodimer-
ization with its mammalian homologs APLP1 and APLP2
promote cell adhesion by trans-cellular interaction in both
S2 cells and mouse embryonic ﬁbroblasts (MEF) (Soba
et al. 2005). In co-immunoprecipitation studies, the well-
conserved E1 domain was identiﬁed as the major interac-
tion interface for dimerization, whereas deletion of the E2
domain had no effect on APP dimerization. The observed
accumulation of APP and APLPs at sites of cell contact
further indicates a direct trans-cellular interaction, a prop-
erty that is even more pronounced for APLP1 and APLP2.
Furthermore, APLP1 was shown to form trans-cellular
interactions in human embryonic kidney (HEK293) cells as
well, whereas trans-cellular interaction of APP and APLP2
could not be detected in this cell system (Kaden et al.
2009). In these cells, heterologously expressed APLP1 was
particularly enriched at the cell surface, whereas both APP
and APLP2 were mainly localized in intracellular com-
partments (Kaden et al. 2009). Thus, the discrepancy is
most likely not due to different trans-interaction properties
but is rather a consequence of different surface localization
of the single APP family members heterologously expres-
sed in kidney ﬁbroblasts. However, these data suggest that
surface localization of APP/APLPs is a major regulator of
their cell adhesion features. Recently, the crystal structure
of the whole E1 domain was resolved, indicating that the
two constituting subdomains GFLD and CuBD interact
tightly and form one functional entity (Dahms et al. 2010).
It was further shown that addition of a deﬁned heparin
induced dimerization of the E1 domain. At least, a deca-
saccharide is required to bridge the positively charged
surface area made up by two opposing GFLD. Therefore, it
is tempting to speculate that extension of the oligosac-
charide would lead to multimerization of APP resulting in
the formation of tetramers and higher order oligomers.
Since heparin is secreted under physiological conditions by
mast cells mediating anticoagulant function, the binding of
heparin by the E1 domain might also stay in context with
the previously described anti-coagulant functions of APP
and APLP2 (Xu et al. 2009). However, heparan sulfate
proteoglycans (HSPG) are structurally related to heparin
and are highly abundant components of the extracellular
matrix (ECM). Thus, it is conceivable that binding of the
E1 domain to HSPG might mediate APP-ECM interac-
tions, as it is well described for other cell adhesion mole-
cules (Kim et al. 2011). However, the in vivo relevance of
heparin-induced APP dimerization remains elusive. Further
investigations, such as introducing single amino acid sub-
stitutions in the heparin-binding domain or testing different
substrates instead of heparin, will be necessary to further
clarify the supposed mechanism of heparin-induced APP
dimerization.
The E2 domain is an independently folded structural
unit of the APP ectodomain consisting of two distinct
coiled coil substructures connected by a continuous central
helix (Wang and Ha 2004). It has been shown by ana-
lytical ultracentrifugation that the E2 domain can revers-
ibly dimerize in solution, and structural data revealed an
antiparallel orientation of the dimer. Remarkably, dimer-
ization of the E2 domain is induced by heparin binding as
well (Lee et al. 2011). However, in the absence of a ligand
like heparin, the monomer thermodynamically predomi-
nates. Notably, antiparallel APP dimerization mediated by
the E2 domain would bring adjacent cells in very close
proximity (approx. 10 nm) as determined by ab initio
reconstruction of molecular models from small angle
X-ray scattering (SAXS) data (Gralle et al. 2006). Hence,
it is rather unlikely that E2-mediated antiparallel dimer-
ization of APP occurs at synapses, although it would be
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20–30 nm) if the polypeptide chain would be elongated to
a maximal extent. Therefore, antiparallel dimerization
mediated by the E2 domain is rather involved in special-
ized cell–cell contacts with minor distances between
adjacent cells like gap junctions. Remarkably, comparison
of the crystal structures of the APP and APLP1 E2 domain
suggests a conserved antiparallel mode of dimerization
within the APP protein family (Lee et al. 2011). However,
further evidence supporting an antiparallel dimerization
mediated by the E2 domain is still lacking. So far, in
hemisynapse formation and in in vitro cell interaction
assays performed with MEF, HEK293 and S2 cells, no
indications for a relevant contribution of the E2 domain
have been observed (Soba et al. 2005; Kaden et al. 2009;
Wang et al. 2009b).
Taken together, there is conclusive evidence from cel-
lular assays and structural information that APP and its
mammalian homologs are able to form dimers in trans
orientation at the cellular level and that dimerization pro-
motes cell adhesion. However, taking into account that
APP normally undergoes rapid proteolytic conversion by
secretases once it reaches the plasma membrane, it will be
important to understand how cell surface localization of the
APP gene family is regulated. Notably, treatment of cells
with phorbol esters like PMA (phorbol 12-myristate
13-acetate) leads to an increased processing of APP as well
as APLPs, indicating that at least a small pool of APP/
APLPs is stabilized at the cell surface and available for
dimerization (Buxbaum et al. 1998; Lammich et al. 1999;
Eggert et al. 2004). This is further supported by the esti-
mation that under steady state levels, about 10% of APP is
located at the plasma membrane (Kuentzel et al. 1993;
Thinakaran and Koo 2008). Alternatively, APP/APLPs
might not function as static cell adhesion molecules but are
rather involved in more dynamic cell adhesion processes
as for instance during neuronal development and/or
synaptogenesis.
Physiological consequences of dimerization
APP dimerization in synaptogenesis
Synapses are specialized intercellular junctions that medi-
ate transmission of information between neurons in the
brain. Synaptic cell adhesion molecules (SAM) are con-
necting the pre- and postsynaptic terminals and mediate
signaling across the synaptic cleft (Dalva et al. 2007).
During synaptogenesis, synaptic cell adhesion molecules
stabilize the initial and/or continuous contact between
axons and dendrites and often mediate recruitment of
additional synaptic proteins.
Does the APP family have similar features like common
SAMs? Notably, APP/APLPs fulﬁll all essential precon-
ditions: (1) They are localized to both the pre- and post-
synaptic site (Kim et al. 1995; Lyckman et al. 1998; Hoe
et al. 2009a). (2) Structural analysis shows that homo- and
heterotypic interactions of APP/APLPs are able to span the
entire synaptic cleft, mediated either by the E1 or, at
maximal extension of the molecule, also by the E2 domain
(Fig. 1). (3) APP expression in HEK293 cells cocultured
with primary hippocampal neurons promotes hemisynapse
formation (Wang et al. 2009b), similar to well-established
SAMs as neuroligins or neurexins (Dean and Dresbach
2006). However, the synaptogenic effect of APP was
considerably smaller (approx. 50%) compared to that of
neuroligin, which might be explained by different expres-
sion levels. Notably, expression of deletion constructs
lacking either the E1 or E2 domain revealed that the syn-
aptogenic activity of APP primarily depends on the E1
domain (Wang et al. 2009b). These ﬁndings are supporting
the idea from structural data and cell aggregation assays
that the E1 domain is the major interaction interface for
trans-dimerization at the synapse (Soba et al. 2005). This
clearly classiﬁes APP/APLPs as SAMs.
This hypothesis is further corroborated by genetic
studies on mice, which are complicated by the overlapping
activities of the single APP family members. Mice deﬁcient
in both APP and APLP2 display defects at the neuromus-
cular junction (NMJ) with an aberrant apposition of pre-
synaptic marker proteins with postsynaptic acetylcholine
receptors and a reduced number of synaptic vesicles at
presynaptic terminals (Wang et al. 2005). Additionally,
tissue-speciﬁc deletion of APP in either presynaptic motor
neurons or postsynaptic muscle cells results in similar
neuromuscular synapse defects, suggesting that APP
expression at both the presynaptic and the postsynaptic
terminal is required for proper development of the NMJ
(Wang et al. 2009b). Further, APP/APLP2 knockout mice
expressing either sAPPa or sAPPb, thus lacking the com-
plete APP intracellular domain, exhibit impaired neuro-
muscular transmission and an aberrant apposition of
pre- and postsynaptic sites at the NMJ, supporting the
assumption that trans-synaptic adhesion of full length APP
is required for proper synapse development (Li et al. 2010;
Weyer et al. 2011).
However, the NMJ is a particular synapse since pre-
synaptic motor neuron and postsynaptic muscle cells are
separated by a basal lamina composed of several glyco-
proteins and proteoglycans (Patton 2003). Therefore, the
synaptic cleft is considerably larger compared to synapses
of the central nervous system. Nevertheless, based on
structural information, a direct trans-cellular interaction of
APP/APLPs is sufﬁcient to span the entire distance of the
synaptic cleft at the NMJ (Fig. 1). However, this interaction
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components of the basal lamina, such as proteoglycans.
Functional analyses at central nerve synapses are further
complicated by the additional presence of APLP1, which is
lacking in the muscle but is most likely present at the
postsynaptic site of CNS synapses (Kim et al. 1995). Fur-
ther, different excitatory or inhibitory synapses might be
affected to different extents, depending on speciﬁc physi-
ological conditions, as, e.g., stability of the synapse. Hence,
defects caused by lack of APP/APLPs might be more subtle
and, therefore, more difﬁcult to detect.
Taken together, the currently available data strongly
support the idea that APP acts as a SAM at central and
peripheral synapses. In this context, APP, APLP1 and
APLP2 might have diverse functions depending on different
subcellular localization and pre- or postsynaptic expression
as well as the propensity to form homo- and heterotypic
dimers. Hence, expression of APP in HEK293 cells cocul-
tured with primary hippocampal neurons of APP/APLP2
double knockout mice revealed that the AICD is dispens-
able at the presynaptic site, whereas both extracellular and
intracellular domains are necessary for synaptogenesis at
the postsynaptic site (Wang et al. 2009b). Interestingly,
neurexin/neuroligin-induced synaptogenesis is supposed to
be mediated by intracellular association partners as well
(Biederer and Sudhof 2000), raising the possibility that the
synaptogenic activity of APP is mediated by intracellular
signaling events similar to other known SAMs.
APP in cell signaling
Due to structural similarities of the GFLD with other
known growth factors and its growth promoting properties,
APP was proposed to act as a cell surface receptor
(Rossjohn et al. 1999). This idea was further supported by
the observation that F-spondin, a neuronally secreted gly-
coprotein implicated in neuronal development, and reelin,
an extracellular matrix protein essential for cortical
development, are binding to the ectodomain of APP,
thereby acting as potential APP ligands (Ho and Sudhof
2004; Hoe et al. 2009b). Moreover, APP undergoes strik-
ingly similar processing as the Notch receptor, leading to
the release of an intracellular domain that translocates to
the nucleus and interacts with certain transcription factors
Fig. 1 APP/APLP trans-dimerization. a Schematic illustration of the
E1 domain-mediated APP dimer spanning intercellular space
between, e.g., pre- and postsynaptic sites (APP695 numbering, aar
amino acid residue). Structures of E1 [protein data bank (PDB) code
3KTM] and E2 (PDB code 1RW6) are shown as rainbow colored
ribbons (blue to red: N- to C-terminus). E1 domain-mediated
dimerization with a second APP molecule (gray subunit) is based
on structural data of the E1 domain according to the PDB code
3KTM. Gray circles illustrate the positions of E1 and E2 domain in
the APP structure. Sizes of unknown linker regions are estimated
based on random coil geometry [rms root mean square, average end-
to-end distance of a random coil polypeptide (Creighton 1993)]. b E2
domain-mediated APP dimer based on 1RW6. The estimated
maximal length of the dimer is about half of the E1 dimer. Notably,
taking available SAXS data into account, calculated rms distances
might overestimate the maximal distance spanned by an APP trans-
dimer under physiological conditions. c Surface potentials of the E1
and E2 dimers (blue positively charged, red negatively charged). Both
dimers form continuous positively charged surface patches favorable
for HSPG binding
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opment (Bray 2006; Konietzko 2011). The AICD includes
an evolutionary conserved YENPTY motif that is impor-
tant for the interaction with several adaptor proteins,
including Fe65, X11/MINT (munc interacting protein), JIP
(JNK interacting protein), Numb and CASK (calcium/cal-
modulin-dependent serine protein kinase) (Jacobsen and
Iverfeldt 2009). Interestingly, neurexin/neuroligin-induced
synaptogenesis is supposed to be mediated by intracellular
association with CASK and X11/MINT (Biederer and
Sudhof 2000), indicating that the synaptogenic activity of
APP is mediated by intracellular signaling events similar to
other synaptic adhesion proteins. The interaction of X11/
MINT with AICD seems to stabilize cellular APP, thus
extending the half-life of the protein. Interestingly, a single
point mutation in the YENPTY motif of APP (Y682G)
diminished the interaction with X11/MINT and abolished
these effects (Borg et al. 1998). In a recent study, a knockin
mouse expressing APP with the same mutation (Y682G)
was crossed to APLP2 knockout mice (Barbagallo et al.
2011). This results in postnatal lethality and neuromuscular
synapse defects considerably similar to those observed in
APP/APLP2 double knockout mice, indicating that tyro-
sine 682 (Y
682) in the cytoplasmic domain of APP is
indispensable for proper neuromuscular synapse formation
and function. Remarkably, the Y682G mutation strongly
reduced the interaction of X11/MINT with APP (Barba-
gallo et al. 2011), further supporting the idea that complex
formation with X11/MINT and CASK is critical for APP
function in synaptogenesis.
Of note, the interaction between APP and most adaptor
proteins depends on phosphorylation of the AICD, either at
threonine 668 (T
668) or tyrosine 682 (Y
682). Phosphoryla-
tion of T
668 leads to structural rearrangements in the
amino-terminal helix (aN) of the AICD (Ramelot and
Nicholson 2001), resulting in reduced binding of the
adaptor proteins as shown for Fe65 (Radzimanowski et al.
2008), the best investigated intracellular binding partner of
APP/APLPs. Fe65 belongs to a gene family with the
mammalian homologs Fe65 like 1 (Fe65L1) and Fe65 like
2 (Fe65L2) (McLoughlin and Miller 2008). Interestingly,
Fe65 co-expression with APP/APLPs promotes cell surface
localization of APP (Sabo et al. 1999, 2001), which in turn
might enhance trans-cellular interaction of APP. In addi-
tion, genetic ablation of Fe65 gene family members in mice
leads to learning deﬁcits (Wang et al. 2004, 2009a).
Moreover, Fe65 has been shown to regulate actin cyto-
skeleton dynamics as well as nuclear gene activation
(Sabo et al. 2001; Cao and Sudhof 2001), linking APP to
different intracellular signaling events possibly involved in
synaptogenesis.
Although further work will be necessary to elucidate
APP/APLP function, our current knowledge of the trans-
cellular interaction properties of APP/APLPs encourage the
hypothesis that APP/APLPs function as dynamic SAMs,
probably not involved in static long-term stabilization of
synapses, but rather in short-term signaling events involved
in synaptogenesis.
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